Data / Form D filings / OverT Bio, Inc.
OverT Bio, Inc.: Form D filings
OverT Bio, Inc., a biotechnology company in New York, NY, filed 2 Form D notices with the SEC between 2023 and 2024. The latest, on May 9, 2024, reports $16 million sold of a $17 million offering to 15 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 430 E 29TH ST 14FL, New York, NY, 10016
- Phone
- (646) 389-7709
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1973901
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 9, 2024 | Amendment | $17,014,920 | $15,989,924 | $1,024,996 | 15 | Apr 4, 2023 | sec.gov |
| May 3, 2023 | New notice | $13,014,927 | $4,487,481 | $8,527,446 | 11 | Apr 4, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Mateusz Legut | Executive Officer, Director | |
| Vasudev Bailey | Director | |
| Sara Choi | Director | |
| Neville Sanjana | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of May 6, 2024 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what OverT Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.